BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 32298469)

  • 1. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
    Parrondo RD; Majeed U; Sher T
    Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancements and future trends of immunotherapy in light-chain amyloidosis.
    Mahadevia H; Ponvilawan B; Sharma P; Al-Obaidi A; Qasim H; Koyi J; Anwer F; Raza S
    Crit Rev Oncol Hematol; 2023 Mar; 183():103917. PubMed ID: 36696931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
    Lakshman A; Kumar SK
    Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daratumumab for the treatment of AL amyloidosis.
    Sidiqi MH; Gertz MA
    Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in AL Amyloidosis.
    Zhang Y; Comenzo RL
    Curr Treat Options Oncol; 2022 Jul; 23(7):1059-1071. PubMed ID: 35635625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
    Su CT; Ye JC
    J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
    Demel I; Bago JR; Hajek R; Jelinek T
    Br J Haematol; 2021 May; 193(4):705-722. PubMed ID: 33216972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AL amyloidosis: untangling new therapies.
    Bal S; Landau H
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):682-688. PubMed ID: 34889374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis.
    Van Doren L; Lentzsch S
    Acta Haematol; 2020; 143(4):373-380. PubMed ID: 32526750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
    Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
    Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis.
    Rosenzweig M; Urak R; Walter M; Lim L; Sanchez JF; Krishnan A; Forman S; Wang X
    Cytotherapy; 2017 Jul; 19(7):861-866. PubMed ID: 28483281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and management of systemic light chain AL amyloidosis.
    Bhutani D; Lentzsch S
    Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement.
    Godara A; Siddiqui NS; Lee LX; Toskic D; Fogaren T; Varga C; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):184-189. PubMed ID: 31983636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
    Vaxman I; Dispenzieri A; Muchtar E; Gertz M
    Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
    Palladini G; Milani P; Malavasi F; Merlini G
    Cells; 2021 Mar; 10(3):. PubMed ID: 33806310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Therapies in AL Amyloidosis-A Glimpse to the Future.
    Haran A; Vaxman I; Gatt ME; Lebel E
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse large B-cell lymphoma: new targets and novel therapies.
    Cheson BD; Nowakowski G; Salles G
    Blood Cancer J; 2021 Apr; 11(4):68. PubMed ID: 33820908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.